Li Junru, Wang Peng, Liu Fei, Li Yuanyuan, Wu Youyou, Wang Fengbo, Du Jundong
Department of General Surgery, Jincheng General Hospital, Jincheng, China.
Cytojournal. 2024 Nov 26;21:55. doi: 10.25259/Cytojournal_105_2024. eCollection 2024.
Pancreatic cancer is characterized by low survival rate and rapid deterioration. Methyltransferase-like 14 (METTL14), as N6-methyladenosine (m6A) methyltransferase, is closely related to tumor progression. The purpose of this study is to look into how METTL14 affects pancreatic cancer tumorigenesis, cell division, and apoptosis.
We examined and contrasted the levels of METTL14 protein and messenger RNA expression in human pancreatic ductal cells and human pancreatic cancer cells. After silencing or upregulating METTL14, the proliferative ability, migration ability, and cell apoptosis of pancreatic tumor cells was detected by colony-forming assay, wound scratch healing assay, cell counting kit 8 assay, and terminal deoxynucleotidyl transferasemediated 2'-deoxyuridine 5'-triphosphate-biotin nick end labeling assay. Following the use of c-Myc inhibitor (10058-F4), western blot analysis was carried out to investigate the key factor expression and c-Myc signaling pathway activation status.
METTL14 was preferentially expressed in human pancreatic cancer cells PANC-1 and SW1990 than in human normal pancreatic duct cells human pancreatic nestin-expressing cells (HPNE) ( < 0.001). Overexpression of METTL14 increased the tumorigenic and proliferative ability of pancreatic cancer cells. Overexpression of METTL14 decreased apoptosis rate. Western blot assay showed that nucleus b-catenin increased when METTL14 was overexpressed, and nucleus b-catenin decreased when METTL14 was silenced in PANC-1 cell ( < 0.01). The protein expression of other key factors, such as c-Myc, matrix metalloproteinase (MMP)-9, and MMP-2, were also affected. The use of c-Myc inhibitor (10058-F4) on the basis of OE-METTL14 reversed the effect of the overexpression of METTL14 on promoting the tumorigenesis and cell proliferation of pancreatic cancer cell lines PANC-1 and SW1990.
METTL14 promoted the tumorigenesis and proliferation of pancreatic cancer cells by the c-Myc signaling pathway.
胰腺癌的特点是生存率低且病情迅速恶化。甲基转移酶样14(METTL14)作为N6-甲基腺苷(m6A)甲基转移酶,与肿瘤进展密切相关。本研究旨在探讨METTL14如何影响胰腺癌的肿瘤发生、细胞分裂和凋亡。
我们检测并对比了人胰腺导管细胞和人胰腺癌细胞中METTL14蛋白及信使核糖核酸的表达水平。在沉默或上调METTL14后,通过集落形成试验、划痕愈合试验、细胞计数试剂盒8试验及末端脱氧核苷酸转移酶介导的生物素化脱氧尿苷三磷酸缺口末端标记试验,检测胰腺肿瘤细胞的增殖能力、迁移能力及细胞凋亡情况。在使用c-Myc抑制剂(10058-F4)后,进行蛋白质印迹分析以研究关键因子表达及c-Myc信号通路的激活状态。
与人类正常胰腺导管细胞人胰腺巢蛋白表达细胞(HPNE)相比,METTL14在人胰腺癌细胞PANC-1和SW1990中优先表达(<0.001)。METTL14的过表达增加了胰腺癌细胞的致瘤性和增殖能力。METTL14的过表达降低了凋亡率。蛋白质印迹试验表明,在PANC-1细胞中,METTL14过表达时细胞核β-连环蛋白增加,METTL14沉默时细胞核β-连环蛋白减少(<0.01)。其他关键因子如c-Myc、基质金属蛋白酶(MMP)-9和MMP-2的蛋白表达也受到影响。在OE-METTL14基础上使用c-Myc抑制剂(10058-F4)可逆转METTL14过表达对胰腺癌细胞系PANC-1和SW1990促肿瘤发生和细胞增殖的作用。
METTL14通过c-Myc信号通路促进胰腺癌细胞的肿瘤发生和增殖。